Marker Therapeutics

Contributing Author

Recent Articles by Marker Therapeutics

Nov-14	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates MRKR GlobeNewswire
Nov-05	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors MRKR GlobeNewswire
Nov-03	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting MRKR GlobeNewswire
Oct-06	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program MRKR GlobeNewswire
Aug-28	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference MRKR GlobeNewswire
Aug-26	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma MRKR GlobeNewswire
Jul-30	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference MRKR GlobeNewswire
Jun-17	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma MRKR GlobeNewswire
May-20	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma MRKR GlobeNewswire
May-19	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies MRKR GlobeNewswire